Is Aravive, Inc. (ARAV) a Buy, Sell, or Hold?
NASDAQ : ARAV
Aravive, Inc. — Institutional Ownership
$0.0401 USD
-$0.01 (-13.39%)
- Volume
- 4.04M
- Average Volume
- 2.16M
- Market Capitalization
- $2.95M
- P/E Ratio
- -0.02
- Dividend Yield
- 0.00%
- Price Target
- $0.25
- Year High
- $2.46
- Year Low
- $0.04
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.73
Institutional Ownership Summary
Institutional Ownership %
%
Investors Holding
change: 0.0 | last:
Increased Positions
change: 0.0 | last:
Reduced Positions
change: 0.0 | last:
New Positions
change: 0.0 | last:
Sold Positions
change: 0.0 | last:
Total Calls
-
Total Puts
-
Put-Call Ratio
change: 0.0 | last:
Total Invested
-
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2023-02-14 | Julian C. Baker | 4.59M | 7.50% |
| 2023-02-14 | Baker Bros. Advisors (GP) LLC | 4.59M | 7.50% |
| 2023-02-14 | Julian C. Baker | 4.59M | 7.50% |
| 2023-02-14 | Baker Bros. Advisors LP | 4.59M | 7.50% |
| 2023-02-14 | Felix J. Baker | 4.59M | 7.50% |
| 2023-02-14 | Felix J. Baker | 4.59M | 7.50% |
| 2023-02-14 | Baker Bros. Advisors LP | 4.59M | 7.50% |
| 2023-02-14 | Baker Bros. Advisors (GP) LLC | 4.59M | 7.50% |
| 2022-11-07 | BVF I GP LLC | 3.91M | 6.40% |
| 2022-11-07 | Biotechnology Value Fund II, L.P. | 1.96M | 3.30% |
| 2022-11-07 | Mark N. Lampert | 6.11M | 9.99% |
| 2022-11-07 | BVF Partners OS Ltd. | 191.37K | 1.00% |
| 2022-11-07 | BVF GP Holdings LLC | 5.87M | 9.60% |
| 2022-11-07 | Biotechnology Value Fund II, L.P. | 1.96M | 3.30% |
| 2022-11-07 | BVF Partners L.P. | 6.11M | 9.99% |
| 2022-11-07 | BVF Inc. | 6.11M | 9.99% |
| 2022-11-07 | Biotechnology Value Trading Fund OS LP | 191.37K | 1.00% |
| 2022-11-07 | BVF II GP LLC | 1.96M | 3.30% |
| 2022-11-07 | BVF GP Holdings LLC | 5.87M | 9.60% |
| 2022-11-07 | Biotechnology Value Fund, L.P. | 3.91M | 6.40% |
| 2022-11-07 | Biotechnology Value Fund, L.P. | 3.91M | 6.40% |
| 2022-11-07 | Biotechnology Value Trading Fund OS LP | 191.37K | 1.00% |
| 2022-11-07 | BVF Partners OS Ltd. | 191.37K | 1.00% |
| 2022-11-07 | BVF Inc. | 6.11M | 9.99% |
| 2022-11-07 | Mark N. Lampert | 6.11M | 9.99% |
| 2022-11-07 | BVF Partners L.P. | 6.11M | 9.99% |
| 2022-11-07 | BVF II GP LLC | 1.96M | 3.30% |
| 2022-11-07 | BVF I GP LLC | 3.91M | 6.40% |
| 2022-11-03 | Fredric N. Eshelman | 26.45M | 43.60% |
| 2022-11-03 | Eshelman Ventures, LLC | 26.38M | 43.50% |
| 2022-04-05 | Fredric N. Eshelman | 10.11M | 34.00% |
| 2022-04-05 | Eshelman Ventures, LLC | 10.07M | 33.90% |
| 2022-02-11 | New Leaf BPO Management II, L.L.C. | 946.42K | 4.50% |
| 2022-02-11 | Hunt | 946.42K | 4.50% |
| 2022-02-11 | Lathi | 946.42K | 4.50% |
| 2022-02-11 | New Leaf Biopharma Opportunities II, L.P. (“Biopharma II”) | 946.42K | 4.50% |
| 2022-02-11 | New Leaf BPO Associates II, L.P. | 946.42K | 4.50% |
| 2022-01-06 | Eshelman Ventures, LLC | 4.27M | 19.87% |
| 2022-01-06 | Fredric N. Eshelman | 4.31M | 19.99% |
| 2021-04-15 | Raymond Tabibiazar | 1.61M | 7.90% |
| 2021-03-23 | Amato Giaccia | 1.18M | 5.90% |
| 2021-02-19 | Qianye Karen Liu | 449.91K | 2.80% |
| 2021-02-19 | BC Axis Limited, as controlled by 3E Bioventures Capital, L.P. | 449.91K | 2.80% |
| 2021-02-16 | 13G | 1.31M | 8.20% |
| 2021-02-16 | 13G | 1.31M | 8.20% |
| 2021-02-16 | 13G | 1.31M | 8.20% |
| 2021-02-16 | 13G | 1.31M | 8.20% |
| 2021-02-16 | 13G | 1.31M | 8.20% |
| 2021-02-16 | 13G | 1.31M | 8.20% |
| 2021-02-16 | 13G | 1.31M | 8.20% |
| 2021-02-16 | 13G | 1.31M | 8.20% |
| 2021-02-16 | 13G | 1.31M | 8.20% |
| 2020-02-13 | 13G | 946.42K | 12.00% |
| 2020-02-13 | 13G | 946.42K | 12.00% |
| 2020-02-13 | 13G | 946.42K | 12.00% |
| 2020-02-13 | 13G | 946.42K | 12.00% |
| 2020-02-13 | 13G | 946.42K | 12.00% |
| 2020-02-13 | 13G | 946.42K | 12.00% |
| 2020-02-13 | 13G | 946.42K | 12.00% |
| 2020-02-13 | 13G | 946.42K | 12.00% |
| 2020-02-13 | 13G | 946.42K | 12.00% |
| 2020-02-13 | 13G | 946.42K | 12.00% |
| 2019-12-10 | Artal International Management S.A. | 1.35M | 9.00% |
| 2019-12-10 | Mr. Pascal Minne | 1.35M | 9.00% |
| 2019-12-10 | Invus Public Equities, L.P. | 1.35M | 9.00% |
| 2019-12-10 | Invus Public Equities Advisors, LLC | 1.35M | 9.00% |
| 2019-12-10 | Stichting Administratiekantoor Westend | 1.35M | 9.00% |
| 2019-12-10 | Stichting Administratiekantoor Westend | 1.35M | 9.00% |
| 2019-12-10 | Mr. Pascal Minne | 1.35M | 9.00% |
| 2019-12-10 | Artal Treasury Limited | 1.35M | 9.00% |
| 2019-12-10 | Invus Public Equities, L.P. | 1.35M | 9.00% |
| 2019-12-10 | Artal International S.C.A. | 1.35M | 9.00% |
| 2019-12-10 | Invus Public Equities Advisors, LLC | 1.35M | 9.00% |
| 2019-12-10 | Artal Treasury Limited | 1.35M | 9.00% |
| 2019-12-10 | Artal International S.C.A. | 1.35M | 9.00% |
| 2019-12-10 | Artal International Management S.A. | 1.35M | 9.00% |
| 2019-12-10 | Artal Group S.A. | 1.35M | 9.00% |
| 2019-12-10 | Westend S.A. | 1.35M | 9.00% |
| 2019-12-10 | Westend S.A. | 1.35M | 9.00% |
| 2019-12-10 | Artal Group S.A. | 1.35M | 9.00% |
| 2018-07-24 | Biopharma Opportunities II, L.P. (“Biopharma II”) | 2.25M | 6.20% |
| 2018-07-24 | Manke | 2.25M | 6.20% |
| 2018-07-24 | Hunt | 2.25M | 6.20% |
| 2018-07-24 | Associates II, L.P. | 2.25M | 6.20% |
| 2018-07-24 | Biopharma Opportunities II, L.P. (“Biopharma II”) | 2.25M | 6.20% |
| 2018-07-24 | Lathi | 2.25M | 6.20% |
| 2018-07-24 | Ratcliffe | 2.25M | 6.20% |
| 2018-07-24 | Management II, L.L.C. | 2.25M | 6.20% |
| 2018-07-10 | (1) BlackRock, Inc. | 1.13M | 3.10% |
| 2018-02-14 | 2. | 1.49M | 4.20% |
| 2018-02-14 | Index Ventures IV (Jersey) L.P. | - | 0.00% |
| 2018-02-13 | Baker Bros. Advisors LP | 1.43M | 4.00% |
| 2018-02-13 | Baker Bros. Advisors (GP) LLC | 1.43M | 4.00% |
| 2018-02-13 | Felix J. Baker | 1.43M | 4.00% |
| 2018-02-13 | Baker Bros. Advisors LP | 1.43M | 4.00% |
| 2018-02-13 | Baker Bros. Advisors (GP) LLC | 1.43M | 4.00% |
| 2018-02-13 | Felix J. Baker | 1.43M | 4.00% |
| 2018-02-13 | Julian C. Baker | 1.43M | 4.00% |
| 2018-02-13 | Julian C. Baker | 1.43M | 4.00% |
| 2018-02-08 | Gabelli Funds, LLC | 311K | 3.10% |
| 2018-02-08 | BARCLAYS GLOBAL INVESTORS, NA. | 529.51K | 4.69% |
| 2018-01-23 | (1) BlackRock, Inc. | 2.03M | 5.70% |
| 2017-10-10 | FMR LLC | - | 0.00% |
| 2017-10-10 | Abigail P. Johnson | - | 0.00% |
| 2017-09-26 | 2 | 2.1M | 5.90% |
| 2017-03-17 | Dr. Michael F. Powell (“Powell”) | 1.66M | 4.70% |
| 2017-03-17 | Sofinnova Management VIII, L.L.C. (“SM VIII”) | 1.66M | 4.70% |
| 2017-03-17 | Dr. James I. Healy (“Healy”) | 1.66M | 4.70% |
| 2017-03-17 | Dr. Anand Mehra (“Mehra”) | 1.66M | 4.70% |
| 2017-03-17 | Sofinnova Venture Partners VIII, L.P. (“SVP VIII”) | 1.66M | 4.70% |
| 2017-02-14 | Joseph Edelman | 4.15M | 11.93% |
| 2017-02-14 | Felix J. Baker | 1.92M | 5.50% |
| 2017-02-14 | Baker Bros. Advisors (GP) LLC | 1.92M | 5.50% |
| 2017-02-14 | Baker Bros. Advisors LP | 1.92M | 5.50% |
| 2017-02-14 | Perceptive Advisors LLC | 4.15M | 11.93% |
| 2017-02-14 | Julian C. Baker | 1.92M | 5.50% |
| 2017-02-14 | Perceptive Life Sciences Master Fund, Ltd. | 3.99M | 11.46% |
| 2017-02-10 | Shahzad Malik | 2.31M | 6.60% |
| 2017-02-10 | Advent Life Sciences Fund I LP | 2.27M | 6.50% |
| 2017-02-10 | Shahzad Malik | 2.31M | 6.60% |
| 2017-02-10 | Advent Life Sciences LLP | 2.27M | 6.50% |
| 2017-02-10 | Advent Life Sciences Fund I LP | 2.27M | 6.50% |
| 2017-02-10 | Advent Life Sciences LLP | 2.27M | 6.50% |
| 2017-02-08 | Index Ventures IV (Jersey) L.P. | 2.17M | 6.24% |
| 2017-02-07 | James I. Healy (“Healy”) | 2.36M | 6.80% |
| 2017-02-07 | Anand Mehra (“Mehra”) | 2.36M | 6.80% |
| 2017-02-07 | Sofinnova Venture Partners VIII, L.P. (“SVP VIII”) | 2.36M | 6.80% |
| 2017-02-07 | Sofinnova Management VIII, L.L.C. (“SM VIII”) | 2.36M | 6.80% |
| 2017-02-07 | Dr. Michael F. Powell (“Powell”) | 2.36M | 6.80% |
| 2017-01-30 | (1) BlackRock, Inc. | 2.22M | 6.40% |
| 2016-12-09 | Julian C. Baker | 2.01M | 5.80% |
| 2016-12-09 | Baker Bros. Advisors (GP) LLC | 2.01M | 5.80% |
| 2016-12-09 | Baker Bros. Advisors LP | 2.01M | 5.80% |
| 2016-12-09 | Felix J. Baker | 2.01M | 5.80% |
| 2016-10-05 | Perceptive Advisors LLC | 4.03M | 13.63% |
| 2016-10-05 | Joseph Edelman | 4.03M | 13.63% |
| 2016-10-05 | Sciences Master Fund, Ltd. | 3.87M | 13.10% |
| 2016-02-26 | BARCLAYS GLOBAL INVESTORS, NA. | 601.46K | 4.49% |
| 2016-02-16 | Julian C. Baker | 3.24M | 11.00% |
| 2016-02-16 | Joseph Edelman | 2.3M | 7.83% |
| 2016-02-16 | Joseph Edelman | 2.3M | 7.83% |
| 2016-02-16 | Perceptive Advisors LLC | 2.3M | 7.83% |
| 2016-02-16 | Felix J. Baker | 3.24M | 11.00% |
| 2016-02-16 | Baker Bros. Advisors LP | 3.24M | 11.00% |
| 2016-02-16 | Perceptive Advisors LLC | 2.3M | 7.83% |
| 2016-02-16 | Baker Bros. Advisors (GP) LLC | 3.24M | 11.00% |
| 2015-02-17 | RA Capital Management, LLC | 231.27K | 1.00% |
| 2015-02-17 | Peter Kolchinsky | 231.27K | 1.00% |
| 2015-02-17 | RA Capital Healthcare Fund, L.P. | 231.27K | 1.00% |
| 2015-02-13 | Index Venture Associates IV Limited | 2.4M | 8.40% |
| 2015-02-13 | Index Ventures IV (Jersey) LP | 2.17M | 7.60% |
| 2015-02-17 | Advent Life Sciences Fund I LP | 2.22M | 9.10% |
| 2015-02-17 | Advent Life Sciences LLP | 2.22M | 9.10% |
| 2015-02-13 | Index Ventures IV (Jersey) LP | 2.17M | 7.60% |
| 2015-02-13 | Index Ventures IV Parallel Entrepreneur Fund (Jersey) LP | 205.97K | 0.70% |
| 2015-02-13 | Index Venture Associates IV Limited | 2.4M | 8.40% |
| 2015-02-17 | Shahzad Malik | 2.22M | 9.10% |
| 2015-02-13 | Index Ventures IV Parallel Entrepreneur Fund (Jersey) LP | 205.97K | 0.70% |
| 2015-02-13 | Yucca (Jersey) SLP | 19159.0 | 0.07% |
| 2015-02-13 | Yucca (Jersey) SLP | 19159.0 | 0.07% |
| 2015-02-10 | 46-3147749 | 2.98M | 10.20% |
| 2015-02-10 | Felix J. Baker | 2.98M | 10.20% |
| 2015-02-10 | Julian C. Baker | 2.98M | 10.20% |
| 2015-02-10 | 46-3147749 | 2.98M | 10.20% |
| 2015-02-10 | 13-4093645 | 2.98M | 10.20% |
| 2015-02-10 | Felix J. Baker | 2.98M | 10.20% |
| 2015-02-10 | Julian C. Baker | 2.98M | 10.20% |
| 2015-02-10 | 13-4093645 | 2.98M | 10.20% |
| 2015-01-29 | REPORTING | 2.14M | 7.50% |
| 2015-01-29 | REPORTING | 2.14M | 7.50% |
| 2015-01-29 | REPORTING | 2.14M | 7.50% |
| 2015-01-29 | REPORTING | 2.14M | 7.50% |
| 2015-01-29 | REPORTING | 2.14M | 7.50% |
| 2015-01-29 | REPORTING | 2.14M | 7.50% |
| 2015-01-29 | REPORTING | 2.14M | 7.50% |
| 2015-01-29 | REPORTING | 2.14M | 7.50% |
| 2015-01-29 | REPORTING | 2.14M | 7.50% |
| 2015-01-29 | REPORTING | 2.14M | 7.50% |
| 2015-01-29 | REPORTING | 2.14M | 7.50% |
| 2015-01-29 | REPORTING | 2.14M | 7.50% |
| 2014-10-10 | Edward C. Johnson 3d | 3.63M | 15.00% |
| 2014-10-10 | Select Biotechnology Portfolio | 1.95M | 8.04% |
| 2014-10-10 | Abigail P. Johnson | 3.63M | 15.00% |
| 2014-10-10 | Edward C. Johnson 3d | 3.63M | 15.00% |
| 2014-10-10 | Select Biotechnology Portfolio | 1.95M | 8.04% |
| 2014-10-10 | FMR LLC | 3.63M | 15.00% |
| 2014-10-10 | FMR LLC | 3.63M | 15.00% |
| 2014-10-10 | Abigail P. Johnson | 3.63M | 15.00% |
| 2014-04-09 | Peter Kolchinsky | 1.4M | 5.80% |
| 2014-04-09 | RA Capital Management, LLC | 1.4M | 5.80% |
| 2014-04-09 | RA Capital Healthcare Fund, L.P. | 1.22M | 5.00% |
| 2014-04-09 | Peter Kolchinsky | 1.4M | 5.80% |
| 2014-04-09 | RA Capital Healthcare Fund, L.P. | 1.22M | 5.00% |
| 2014-04-09 | RA Capital Management, LLC | 1.4M | 5.80% |
| 2014-04-07 | Dr. Srinivas Akkaraju (“Akkaraju”) | 2.15M | 8.90% |
| 2014-04-07 | Sofinnova Venture Partners VIII, L.P. (“SVP VIII”) | 2.15M | 8.90% |
| 2014-04-07 | Sofinnova Management VIII, L.L.C. (“SM VIII”) | 2.15M | 8.90% |
| 2014-04-07 | Dr. James I. Healy (“Healy”) | 2.15M | 8.90% |
| 2014-04-07 | Dr. Michael F. Powell (“Powell”) | 2.15M | 8.90% |
| 2014-04-07 | Dr. Anand Mehra (“Mehra”) | 2.15M | 8.90% |
ARAV Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2022-12-31 | $1.32 | 36.37M | $48.01M | $53.69M | $6.27M | $594.04K |
| 2021-12-31 | $2.19 | 20.07M | $43.95M | $59.42M | $6.37M | -$9.1M |
| 2020-12-31 | $5.64 | 15.79M | $89.06M | $60.54M | $8.52M | $37.03M |
| 2019-12-31 | $13.67 | 11.59M | $158.42M | $65.13M | $10.23M | $103.52M |
| 2018-12-31 | $3.52 | 7.17M | $25.24M | $56.99M | $7.32M | -$24.43M |
| 2017-12-31 | $13.20 | 5.87M | $77.5M | $81.15M | $5.43M | $1.78M |
| 2016-12-31 | $89.40 | 5.13M | $458.68M | $201.15M | -$ | $257.53M |
| 2015-12-31 | $74.34 | 4.83M | $358.86M | $182.07M | -$ | $176.79M |
| 2014-12-31 | $134.70 | 3.15M | $424.8M | $170.57M | -$ | $254.23M |
| 2013-12-31 | $188.22 | 3.88M | $729.81M | $13.21M | $500K | $717.09M |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2023-09-30 | $0.13 | 75.74M | $10M | $8.54M | $2.43M | $3.89M |
| 2023-06-30 | $1.26 | 99.64M | $125.54M | $18.36M | $2.97M | $110.15M |
| 2023-03-31 | $2.00 | 75.72M | $151.43M | $35.92M | $3.52M | $119.02M |
| 2022-12-31 | $1.32 | 62.94M | $83.08M | $53.69M | $6.27M | $35.66M |
| 2022-09-30 | $0.82 | 30.52M | $24.93M | $27.9M | $4.65M | $1.68M |
| 2022-06-30 | $0.99 | 30.29M | $29.93M | $46.83M | $5.21M | -$11.7M |
| 2022-03-31 | $1.93 | 21.13M | $40.78M | $65.82M | $5.79M | -$19.26M |
| 2021-12-31 | $2.19 | 21M | $45.99M | $59.42M | $6.37M | -$7.07M |
| 2021-09-30 | $3.72 | 20.76M | $77.24M | $67.51M | $6.97M | $16.7M |
| 2021-06-30 | $5.98 | 20.41M | $122.08M | $75.44M | $7.63M | $54.27M |
| 2021-03-31 | $6.59 | 18.07M | $119.06M | $78.68M | $8.24M | $48.62M |
| 2020-12-31 | $5.64 | 16.18M | $91.27M | $60.54M | $8.52M | $39.25M |